Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2

Conditions

Pruritus 2Piebaldism 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Mastocytosis, Systemic 2Mastocytosis 2Gastrointestinal Stromal Tumors 2Blushing 2Recurrence 1Multiple Myeloma 1Metastatic Castrate Resistant Prostate Cancer 1Melanoma 1Gastro-Intestinal Stromal Tumour 1Colorectal Neoplasms 1

Interventions

masitinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Blushing × masitinib × Clear all
NCT04333108 2023-05-06

Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment

AB Science

Phase 3 Unknown
140 enrolled
Myeloid

Blushing, Mastocytosis, Pruritus, Piebaldism, Mastocytosis, Systemic

NCT00814073 2019-12-03

AB06006

AB Science

Phase 3 Completed
135 enrolled
Myeloid

Blushing, Mastocytosis, Pruritus, Piebaldism, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡